Correction to: Novel immunotherapeutics against LGR5 to target multiple cancer types (EMBO Molecular Medicine, (2024), 16, 9, (2233-2261), 10.1038/s44321-024-00121-2)

Hung Chang Chen, Nico Mueller, Katherine Stott, Chrysa Kapeni, Eilidh Rivers, Carolin M. Sauer, Flavio Beke, Stephen J. Walsh, Nicola Ashman, Louise O’Brien, Amir Rafati Fard, Arman Ghodsinia, Changtai Li, Fadwa Joud, Olivier Giger, Inti Zlobec, Ioana Olan, Sarah J. Aitken, Matthew Hoare, Richard MairEva Serrao, James D. Brenton, Alicia Garcia-Gimenez, Simon E. Richardson, Brian Huntly, David R. Spring, Mikkel Ole Skjoedt, Karsten Skjødt, Marc de la Roche*, Maike de la Roche*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

The 12th author’s name is corrected. The 12th author’s name is corrected from: Arman Godsinia To: (Changes in bold). Arman Ghodsinia The original article has been corrected.

Original languageEnglish
Pages (from-to)3026
Number of pages1
JournalEMBO Molecular Medicine
Volume16
Issue number11
DOIs
Publication statusPublished - 11 Nov 2024
Externally publishedYes

Fingerprint

Dive into the research topics of 'Correction to: Novel immunotherapeutics against LGR5 to target multiple cancer types (EMBO Molecular Medicine, (2024), 16, 9, (2233-2261), 10.1038/s44321-024-00121-2)'. Together they form a unique fingerprint.

Cite this